Pharmacogenomics of the triazole antifungal agent voriconazole.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveVoriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipientsPharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicineImpact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity.Understanding and preventing drug-drug and drug-gene interactions.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Pharmacogenomics of antimicrobial agents.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.Outbreak of fungal endophthalmitis due to Fusarium oxysporum following cataract surgery.In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B.Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults.Value of Supportive Care Pharmacogenomics in Oncology Practice.
P2860
Q27009221-DE99B8D3-80D9-43A9-BE2B-E2BC07FCF884Q27012442-D412D30F-7D61-43A2-8C05-CD81C861CD43Q27692687-AC8287D4-F52F-4DED-9CA0-ADC89C14B91AQ30491969-26903582-6BAD-479E-827A-573A27DF8FECQ33684379-069FB129-41A4-4FCB-A8B1-B6BB3D4B8BF3Q33849298-13277A9A-F320-4111-959B-5A7769C78984Q34034599-8AF2FE4D-2DC7-43F5-90AD-DC292656D830Q34415944-116D604B-7492-497A-80B6-9E346E6323D8Q34532546-7C7737E1-D1CF-4D76-B052-5252803E87C8Q34977413-6AEB18A5-AFF5-4338-B048-005C31D04F95Q35086478-50CD270B-CB2C-475C-AEB8-0DDE48CD4A92Q36673940-4D3240BD-B0E8-42A6-B465-EABDCC3A9BE6Q38284468-0D738588-8901-433C-977B-DCCE85EA1686Q38813187-746D8EFA-2A8E-4A3F-984D-713601705640Q40562624-35FE4C62-C65B-476D-AF44-C68BB2DFF10DQ41564182-407F48D8-99FA-41E9-B5F6-ADAFEAD69BC8Q41595490-2113EF6B-C51B-4132-9929-C1B96ADFEB0CQ42234620-BF721552-0816-48A7-A1E5-BAFBA876E58BQ43571902-563AAEE3-0271-4536-92E9-C27C0FC137BDQ45160680-CA7EB599-5CFF-4C08-A08D-13A3E60BEC70Q46119145-098C8CB2-144E-4926-8C40-B7FC3EE615BFQ47635280-76034AC2-C9DD-4161-AF08-D7D976DD27C8Q47664190-3BB0CA92-0592-41BE-BA4B-A46BFAF60D35Q50112710-241BE7E5-D143-4D38-97C6-3D3E134D8AF5Q52603826-A7D5A961-57E0-4BF1-B53F-F9BF1EFA49DD
P2860
Pharmacogenomics of the triazole antifungal agent voriconazole.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenomics of the triazole antifungal agent voriconazole.
@en
Pharmacogenomics of the triazole antifungal agent voriconazole.
@nl
type
label
Pharmacogenomics of the triazole antifungal agent voriconazole.
@en
Pharmacogenomics of the triazole antifungal agent voriconazole.
@nl
prefLabel
Pharmacogenomics of the triazole antifungal agent voriconazole.
@en
Pharmacogenomics of the triazole antifungal agent voriconazole.
@nl
P2860
P356
P1433
P1476
Pharmacogenomics of the triazole antifungal agent voriconazole.
@en
P2093
Ina Maria Scholz
Johanna Weiss
P2860
P304
P356
10.2217/PGS.11.18
P50
P577
2011-06-01T00:00:00Z